Aposense, Ltd. (fka NeuroSurvival Technologies, Ltd.) has developed a series of molecules that selectively target and accumulate within dying, or apoptotic cells. The molecules, which use the trade name Aposense, can carry a therapeutic compound to the site of cancer cells. The company is seeking regulatory approval for its first commercial application of its therapeutic agent and has additional compounds under development.